EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence

Wenhui Xie, Tong Chen, Shiyu Xiao, Hong Huang, Zhuoli Zhang

Annals of the Rheumatic Diseases · 2026-03 · 85 (3) · 417-424

DOI: 10.1016/j.ard.2025.10.007 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of the Rheumatic Diseases, 2026-03. Verfasst von Wenhui Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China; National Clinical Research Center for Skin and …. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Despite significant advances in targeted therapies, difficult-to-treat rheumatoid arthritis (D2T-RA) remains a major clinical challenge. This study aimed to systematically evaluate the global prevalence of D2T-RA using the European League Against Rheumatism (EULAR) definition and to quantify the proportion attributable to persistent inflammatory refractory rheumatoid arthritis (RA). METHODS: We comprehensively searched PubMed, EMBASE, and Cochrane Library (up to April 2025) for observational studies reporting the prevalence of D2T-RA according to the EULAR definition. Subgroup analyses were performed to explore heterogeneity sources. Random-effects meta-analysis of proportions using generalised linear mixed models was conducted to calculate pooled prevalence rates and 95% CI. RESULTS: Twenty-three studies with 27,987 patients with RA from 13 countries were included. The global pooled prevalence of D2T-RA was 11.7% (95% CI: 9.5%-14.3%). The pooled prevalence of D2T-RA was 10.9% (95% CI: 8.2%-14.2%) in overall RA cohorts and 13.2% (95% CI: 9.1%-18.8%) in studies restricted to biologic and target synthetic disease-modifying antirheumatic drugs (b/tsDMARDs)-treated populations. D2T-RA prevalence was stable in the region, RA criteria, and study setting; significant variations only existed in the enrolled period (pre-2020 vs post-2020: 9.86% [95% CI: 7.6%-12.7%] vs 14.3% [95% CI: 10.3%-19.6%]; P = .08). Moreover, about half of patients with D2T-RA exhibited evidence of persistent inflammatory refractory RA (pooled proportion: 47.1%, 95% CI: 33.3%-61.4%). Prevalence decreased sharply with stricter definitions: D2T(3)-RA (≥3 b/tsDMARD failures): 4.3% (2.7%-6.7%) and D2T(4)-RA (≥4 failures: 1.6% (0.6%-4.3%). CONCLUSIONS: Based on available global data, approximately 12% of patients with RA meet standard D2T-RA criteria, with nearly half exhibiting persistent inflammatory disease. Stricter definitions with failure of ≥3 b/tsDMARD identify the small group of patients for whom innovative treatments or strategies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsHumansPrevalenceGlobal HealthBiological Products

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
  • Department of Gastroenterology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Clinical Immunology Translation Medicine Key Laboratory…
  • Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China. Electronic address: zhuoli.zhang@126.…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xie, W., Chen, T., Xiao, S., Huang, H., & Zhang, Z. (2026). Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence. Annals of the Rheumatic Diseases, 85(3), 417-424. https://doi.org/10.1016/j.ard.2025.10.007

Vancouver

Xie W, Chen T, Xiao S, Huang H, Zhang Z. Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence. Annals of the Rheumatic Diseases. 2026;85(3):417-424. doi:10.1016/j.ard.2025.10.007

BibTeX
@article{Xie2026,
  author = {Xie, Wenhui and Chen, Tong and Xiao, Shiyu and Huang, Hong and Zhang, Zhuoli},
  title = {Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {3},
  pages = {417--424},
  doi = {10.1016/j.ard.2025.10.007}
}
Kostenlos starten →